Our results demonstrated that pharmaceutical activation of the PI3K/AKT signaling pathway could counteract the suppressive effects of COL22A1 gene silencing on the aggressive behavior of GBM cells, further highlighting the crucial role of this oncogenic pathway in sustaining GBM malignancy. The gene discussed is AKT1; the disease is glioblastoma.